Navigation Links
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Date:9/14/2010

RICHMOND, Calif., Sept. 14 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic™ development programs and an overview of the company's business strategy at two investor conferences during the month of September:

  • The UBS Global Life Sciences Conference, at 4:00 pm ET on Tuesday, September 21.
  • The Fifth Annual JMP Securities Healthcare Conference, at 9:00 am ET on Tuesday, September 28.

Live webcasts of the presentations will be available on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. A replay of each presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and a Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
2. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
3. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
4. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
5. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
6. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
7. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
8. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
9. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
10. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
11. Sangamo Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... LOS ANGELES, CA (PRWEB) , ... June 28, ... ... its presence in the international market with three research projects accepted for presentation ... and Embryology (ESHRE) . Nearly 10,000 participants – including some of the world’s ...
(Date:6/28/2017)... (PRWEB) , ... June 28, ... ... Siemens’ STAR-CCM+® software for multiphysics computational fluid dynamics (CFD) simulation and analysis ... and optimization. STAR-CCM+ version 12.04 introduces Design Manager, allowing users to easily ...
(Date:6/28/2017)... ... June 28, 2017 , ... Studies indicate that replacing ... an effective treatment for Parkinson’s disease. But what has not been determined is the ... to gain the best results. , A new study coming out of Singapore, recently ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... mirroring wellness product via Kickstarter campaign on June 15th to fund production of ... the B2v2, exceeding the original Kickstarter goal by more than 150% in a ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
Breaking Biology News(10 mins):